Trial · NCT05214001
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
NCT05214001, Phase 4, Terminated, Messoud Ashina, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine. Trials, record NCT05214001. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05214001
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
- NCT number
- NCT05214001
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 8 participants, actual
- Lead sponsor
- Messoud Ashina, MD
- Conditions
- Migraine With Aura, Migraine Without Aura
- Interventions
- Almotriptan 12.5 Mg Oral Tablet, Ubrogepant 50Mg Tab
- First posted
- 2022-01-28
- Last updated
- 2025-05-31
- Other registries' IDs
- eudract:2021-001087-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain freedom at 2 hours | 2 hours after initial dose | Pain freedom will be subjectively rated by the patient in a headache diary (yes or no). |
| Other | Absence of the most bothersome symptom (MBS) at 2 hours | 2 hours after initial dose | Patients are to select their MBS prior to randomization, and then only treat an attack that occurs with the pre-specified MBS. 2 hours after initial dose, patients are to subjectively rate if the MBS have disappeared fully or if it is still present (present or not present). |
| Other | Relapse | 48 hours after initial dose | Patients, who were pain free 2 hours after the investigational treatment was administered, are to subjectively evaluate if they experienced reoccurrence of headache of any severity within 48 hours of the intake of given treatment (relapse of headache or no headache). |
| Other | Headache intensity | Predose, and 0.5, 1, 1.5, 2, 3, 4, 12, 24 and 48 hours after initial dose | Headache intensity will be subjectively rated by the patient at predefined timepoints on a 4-point scale where 0 = no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache. |
| Other | Rescue medication | 48 hours after initial dose | The patient will record if they take any rescue medication 2 hours after intake of test medication and within 48 hours. |
| Other | Global evaluation | 48 hours after initial dose | The patient will subjectively rate their global impression of the test medication based on Likert-type verbal scale (e.g., very poor, poor, no opinion, good, very good). |
| Other | Associated symptom - nausea | Predose, 2, 4, 8, 12, 24- and 48-hours after initial dose | The presence or absence of nausea. |
| Other | Associated symptom - photophobia | Predose, 2, 4, 8, 12, 24- and 48-hours after initial dose | The presence or absence of photophobia. |
| Other | Associated symptom - phonophobia | Predose, 2, 4, 8, 12, 24- and 48-hours after initial dose | The presence or absence of phonophobia. |
| Other | Adverse events | Up to 48 hours after initial dose. | Any untowards medical events are to be recorded in the diary by the patients. Furthermore, the patient will be instructed to inform the investigator in such case. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05214001
GET https://conductscience.org/api/trials/v1/NCT05214001/registered